TrialCA: a cancer journal for clinicians

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

Jian-Chun Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.